Molecular Cancer

Table 2 Correlation between PIK3CA-110-Alpha status and clinicopathological features in Epithelial Ovarian Carcinoma

From: PIK3CA alterations in Middle Eastern ovarian cancers

			High p110 α expression		Low p110 α expression		P value
	N	%	N	%	N	%
Total Number of Cases	140		78	55.7	62	44.3
Age
< = 50 years	54	38.6	31	57.4	23	42.6	0.7491
> 50 years	86	61.4	47	54.7	39	45.3
Tumour Stage
Stage I-II	8	6.1	4	50.0	4	50.0	0.7525
Stage III-IV	122	93.9	68	55.7	54	44.3
Histopathology
Clear cell	4	2.9	3	75.0	1	25.0	0.8585
Endometriod	19	13.6	11	57.9	8	42.1
Serous	113	80.7	62	54.9	51	45.1
Undifferentiated	4	2.9	2	50.0	2	50.0
FIGO Grade
Well differentiated	27	19.3	12	44.4	15	55.6	0.4114
Moderately Diff	73	52.1	42	57.5	31	42.5
Poorly Diff	40	28.6	24	60.0	16	40.0
PAKT (Ser473)
High (2–3)	69	51.5	46	66.7	23	33.3	0.0260
Low (0–1)	65	48.5	31	47.7	34	52.3
PTEN
Low (0–1)	31	23.3	17	54.8	14	45.2	0.7675
High (2–3)	102	76.7	59	57.8	43	42.2
Ki-67
Above 50	51	37.0	34	66.7	17	33.3	0.0639
Below = 50	87	63.0	44	50.6	43	49.4
P53
Negative	65	50.0	37	56.9	28	43.1	0.5923
Positive	65	50.0	40	61.5	25	38.5
KRAS Mutation
Present	2	1.4	0	0.0	2	100.0	0.0720
Absent	136	98.6	76	55.9	60	44.1
BRAF Mutation
Present	3	2.1	1	33.3	2	66.7	0.4302
Absent	137	97.9	77	56.2	60	43.8
PIK3CA Mutation
Present	6	4.4	5	83.3	1	16.7	0.1298
Absent	131	95.6	70	53.4	61	46.6
P53 Mutation
Present	47	34.1	25	53.2	22	46.8	0.7497
Absent	91	65.9	51	56.0	40	44.0
PIK3CA FISH
Amplified	49	35.5	24	49.0	25	51.0	0.2320
Non-Amplified	89	64.5	53	59.6	36	40.4
PFS-Median (months)			16.2		17.1		0.6578

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com